Suppr超能文献

经内镜超声获取的治疗初治胰腺导管腺癌的治疗诊断性染色体重排

Theragnostic chromosomal rearrangements in treatment-naive pancreatic ductal adenocarcinomas obtained via endoscopic ultrasound.

机构信息

Biomarker Discovery Laboratory, Centre for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.

Division of Gastroenterology & Hepatology, Mayo Clinic, Rochester, MN, USA.

出版信息

J Cell Mol Med. 2021 Apr;25(8):4110-4123. doi: 10.1111/jcmm.16381. Epub 2021 Mar 11.

Abstract

A crucial mutational mechanism in malignancy is structural variation, in which chromosomal rearrangements alter gene functions that drive cancer progression. Herein, the presence and pattern of structural variations were investigated in twelve prospectively acquired treatment-naïve pancreatic cancers specimens obtained via endoscopic ultrasound (EUS). In many patients, this diagnostic biopsy procedure and specimen is the only opportunity to identify somatic clinically relevant actionable alterations that may impact their care and outcome. Specialized mate pair sequencing (MPseq) provided genome-wide structural variance analysis (SVA) with a view to identifying prognostic markers and possible therapeutic targets. MPseq was successfully performed on all specimens, identifying highly rearranged genomes with complete SVA on all specimens with > 20% tumour content. SVA identified chimeric fusion proteins and potentially immunogenic readthrough transcripts, change of function truncations, gains and losses of key genes linked to tumour progression. Complex localized rearrangements, termed chromoanagenesis, with broad pattern heterogeneity were observed in 10 (83%) specimens, impacting multiple genes with diverse cellular functions that could influence theragnostic evaluation and responsiveness to immunotherapy regimens. This study indicates that genome-wide MPseq can be successfully performed on very limited clinically EUS obtained specimens for chromosomal rearrangement detection and potential theragnostic targets.

摘要

在恶性肿瘤中,一个关键的突变机制是结构变异,其中染色体重排改变了驱动癌症进展的基因功能。在此,通过内镜超声(EUS)对 12 个前瞻性获得的未经治疗的胰腺癌标本进行了结构变异的存在和模式的研究。在许多患者中,这种诊断性活检程序和标本是唯一能够识别体细胞临床相关的可操作改变的机会,这些改变可能会影响他们的治疗和预后。专门的配对末端测序(MPseq)提供了全基因组结构变异分析(SVA),以确定预后标志物和可能的治疗靶点。所有标本均成功进行了 MPseq,对所有肿瘤含量>20%的标本进行了完整的 SVA,鉴定了高度重排的基因组。SVA 鉴定了嵌合融合蛋白和潜在的免疫原性通读转录本、功能缺失截断、关键基因的增益和丢失,这些基因与肿瘤进展有关。在 10 个(83%)标本中观察到复杂的局部重排,称为染色体重组,具有广泛的模式异质性,影响多种具有不同细胞功能的基因,这可能影响治疗评估和对免疫治疗方案的反应性。本研究表明,MPseq 可以成功地在非常有限的临床 EUS 获得的标本上进行,以检测染色体重排和潜在的治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0ac/8051743/a8527ffde6c6/JCMM-25-4110-g004.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验